Therapies to prevent progression of COVID-19 in outpatients: The 'Primary Care Australian COVID-19 Therapeutics' (PACT) Trial

Phase 1

Recruiting

• Conditions: COVID-19; Infection - Other infectious diseases; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12622000386730
• Lead Sponsor: AProf Dr Karin Ried

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-04
• Last Update Posted: 28 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

•COVID-19 diagnosis in the preceding 4 days (RAT positive or PCR positive)
•At least 40 years old

Exclusion Criteria

•Women who are pregnant, breastfeeding or actively trying to achieve a pregnancy
•Current hospital inpatient with COVID-19 related disease
•Allergy to ivermectin, doxycycline or famotidine
•Known bleeding disorder
•Known severe liver disease
•Diagnosis of Myasthenia Gravis/SLE
•Consumption of grapefruit juice
•Ever travelled to countries that are endemic for Loa loa (West and Central Africa – Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Ethiopia, Guinea, Gabon, Republic of Congo, Nigeria and Sudan)
•Currently on the following medications:
oCardiac - quinidine, amiodarone, diltiazem, verapamil, warfarin
oAnti-infective – clarithromycin, erythromycin, itraconazole, ketoconazole,
oAnti-viral – indinavir, ritonavir, cobicistat
oDisease modifying – cyclosporine, tacrolimus, sirolimus, methotrexate
oOther – retinoids, lithium, spironlactone

Neither minority groups nor NESB/LOTE persons will be excluded provided they possess the capacity (ie ability to understand, retain, comprehend and dutifully consider a response) to consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified